- Graham Kyle, consultant ophthalmologist1
- 1Liverpool L1 9AR, UK
- grahamkyle33{at}gmail.com
Jackson and Kirkpatrick recommend adopting cheaper bevacizumab over more expensive ranibizumab to treat wet age related macular degeneration.1 However, their cost projections “do not consider any potential differences in safety, medicolegal risk, treatment burden, or patient preference . . . .”
The medicolegal risks of such an adoption are considerable, not least for …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Hormone replacement therapy - psychiatric aspects
Published 22 February 2012
Re: Assaulting alternative medicine: worthwhile or witch hunt?
Published 22 February 2012
Re: Raised inflammatory markers
Published 22 February 2012
Re: Assaulting alternative medicine: worthwhile or witch hunt?
Published 22 February 2012
Re: Improving the delivery of safe and effective healthcare in low and middle income countries
Published 22 February 2012
Most responses
Assaulting alternative medicine: worthwhile or witch hunt? (12 responses)
Published 15 Feb 2012
Shared decision making: really putting patients at the centre of healthcare (8 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (8 responses)
Published 1 Feb 2012
Raised inflammatory markers (7 responses)
Published 3 Feb 2012
Independence in disciplinary proceedings against doctors (5 responses)
Published 24 Jan 2012